Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension

Model scores of the 29,894 trials active now.

Model score 27% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularleftcardiacpatientinfusion
  Phrases that lowered it: bodymedicinechildrenbloodsubjects
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Minimum age: not given (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 33 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 43.0% (raises risk) · Drug's FDA history
• Maximum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 97.2% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Number of arms: not given (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Blinding: none (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Collaborators: 0 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 396 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension NCT04039464 · started 2022 · scored riskier than 74% of active trials completed
• A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension NCT01484431 · started 2012 · scored riskier than 82% of active trials completed
• The Assessment of Right Ventricular Contractility in Response to Sildenafil NCT00742014 · started 2008 · scored riskier than 27% of active trials terminated
• Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension NCT02216279 · started 2014 · scored riskier than 26% of active trials completed
• Oral Sildenafil and Intravenous Milrinone on Postoperative Pulmonary Hypertension NCT02595541 · started 2015 · scored riskier than 17% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.